ASK Pharmaceuticals

Asklepios BioPharmaceutical (AskBio), a wholly owned subsidiary of Bayer AG, is a pioneer in the field of gene therapy, specializing in the development of Adeno-Associated Virus (AAV) based treatments. Founded in 2001 by Dr. Jude Samulski, the first scientist to clone AAV for therapeutic use, the company maintains an industry-leading technology suite including the Pro10™ manufacturing platform and an extensive library of synthetic capsids. AskBio’s clinical pipeline targets high-unmet-need conditions such as Parkinson’s disease, congestive heart failure, and Pompe disease, utilizing advanced genetic engineering to deliver long-term therapeutic benefits. Following its acquisition by Bayer in 2020 for $2 billion upfront, the company continues to operate as an independent entity, driving innovation in genomic medicine from its headquarters in Research Triangle Park, North Carolina.